Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "diabetes"

488 News Found

Lupin to settle litigations over diabetes drug
News | September 16, 2021

Lupin to settle litigations over diabetes drug

The board has approved the settlement of US $ 248 million towards Direct Purchaser group and Retailer Opt-Out group subject to court approval


Novartis announces positive results from Phase 3 trials of Beovu for diabetes
Drug Approval | August 18, 2021

Novartis announces positive results from Phase 3 trials of Beovu for diabetes

Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one


India observes its first `Prediabetes Day' on August 14
Healthcare | August 14, 2021

India observes its first `Prediabetes Day' on August 14

Fitterfly has launched an online Prediabetes risk test which is an evidence-based, clinically validated tool for assessing an individual's risk of Prediabetes


Zydus launches affordable Semaglutide in India after patent expiry
News | March 23, 2026

Zydus launches affordable Semaglutide in India after patent expiry

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders


Zydus and Torrent Pharma to co-market Semaglutide injection in India
News | March 19, 2026

Zydus and Torrent Pharma to co-market Semaglutide injection in India

Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device


Zydus, Lupin join forces to expand access to semaglutide in India
News | March 18, 2026

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus


GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
News | March 16, 2026

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk


Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer
Clinical Trials | March 16, 2026

Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer

The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months


First patient dosed in trial of novel drug targeting limb-threatening artery disease
News | March 16, 2026

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts